An observational study in Autism Spectrum Disorder, sponsored by IRCCS Eugenio Medea. Recruiting at 2 sites in Italy. Open to participants aged 18 Months to 60 Months. Per ClinicalTrials.gov, last updated 2026-03-24.
Sponsored by IRCCS Eugenio Medea · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 90 studies in Autism Spectrum Disorder with a site in Italy — 48 open to participants now, 55 under way, 1 of them phase 3. Autism Spectrum Disorder · Italy.
Among the 90 studies in Autism Spectrum Disorder with a site in Italy, this one is the 4th largest by planned enrollment of the 27 observational ones that give a count, is one of 6 that started in 2025, is one of 27 observational ones, reaches primary completion later than 43 of the 54 other live ones, and was the 84th registered.
1,733 studies on the registry are indexed under Autism Spectrum Disorder; 503 are open to participants now.
Browse Autism Spectrum Disorder studies →48 of the 90 studies in Autism Spectrum Disorder with a site in Italy are open now. Recruiting first, the newest first:
University of Milan · Sites in Italy
Ages 6–14
IRCCS San Raffaele Roma · Sites in Italy
Ages 2–18 · Healthy volunteers
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 6–13
Antonella Costantino · Sites in Italy
Ages 0–11
Istituto per la Ricerca e l'Innovazione Biomedica · Sites in Italy
Ages 4–12 · Healthy volunteers
A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →
Of the 351 Autism Spectrum Disorder studies recruiting now, 48 (14%) set no upper age limit and 296 (84%) stop at 75 or younger; 301 take children under 18; 92 take healthy volunteers.
This study: 18 Months to 60 Months · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
90 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 9 · Phase 3 6
First in 2012; this study’s year is marked. 6 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 200 is above the median of 103 across 323 observational studies indexed under Autism Spectrum Disorder.
Median enrollment 50 across the 63 interventional studies, 100 across the 27 observational. Of the 31 that completed or were terminated, 8 (26%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 90 have an industry lead sponsor. The 10 most frequent:
IRCCS Eugenio Medea is the lead sponsor of 109 studies on the registry; 52 are open to participants now.
IRCCS Eugenio Medea has 9 studies filed under Autism Spectrum Disorder — fewer than ten, so there is no comparison to draw.
11 of the studies in Autism Spectrum Disorder with a site in Italy that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06514573Istituto Superiore di SanitàButyrate Supplementation in Children With Autism Spectrum Disorder (ASD) and Functional Gastrointestinal Disorders | 2026-11 |
| NCT07519369IRCCS San Raffaele RomaMonitoring Daily Mobility in Children With Autism | 2026-12 |
| NCT07389720IRCCS Eugenio MedeaCharacterization of (A)Typical Sensorimotor Pathways in Individuals With Autism | 2026-12 |
| NCT07470138IRCCS Eugenio MedeaSleep Disturbance in Subjects With Autism Spectrum Disorders (ASD) in Preschool Age (18-60 Months) | 2026-12-15 |
| NCT07643649Istituto per la Ricerca e l'Innovazione BiomedicaCognitive Training in Virtual Reality for Autism | 2026-12-31 |
Add all 11 to your calendar (.ics) → With an account.
Among the 90 studies in Autism Spectrum Disorder with a site in Italy, from their registry updates:
This tab as a report to print or save as PDF → With an account.
An observational study is one that aims to collect data from routine clinical practice, without altering a patient's standard diagnostic and therapeutic pathway (no additional instrumental or laboratory tests beyond those performed in clinical practice are envisaged).
The overall objective of this study is to investigate sleep disorders in preschool-aged children with Autism Spectrum Disorder. Sleep plays a key role in early brain development. The prevalence of sleep disorders in childhood is reported to be between 10 and 50%, with a prevalence of up to 86% in children with neurodevelopmental disorders. Over the past few decades, numerous studies have demonstrated a significant bidirectional connection between sleep problems and various areas of child development. Therefore, early identification of sleep disorders in childhood is essential for adequate treatment and prevention of negative cognitive and socioemotional impacts.
Recent studies have demonstrated a hypothetical role for vitamin D and iron in regulating sleep. The objectives of the study are to describe sleep disturbances in a group of preschool-aged subjects with ASD (18-60 months), to measure blood ferritin and vitamin D levels, and to assess a possible correlation with specific subtypes of sleep disturbances.
Given the impact that sleep disturbances have on various areas of children's development, secondary objectives include assessing a possible positive correlation between the severity of sleep disturbances and symptoms related to Autism Spectrum Disorder and/or other psychiatric comorbidities.
subjects with ASD aged between 18 months and 60 months
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
- Subjects with neurologica theraphy
Other: follow up
clinical evaluation as usual
Sleep Disturbance Scale for Children
Sleep disturbances will be assessed using the Sleep Disturbance Scale for Children (SDSC) in the 3-6 year version and the 6 months-3 years version
Time frame: once at enrolment
Started Jan 2025 (actual). Primary completion is estimated for Dec 2026, 23 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.